GLP-1 Plateau Management
AGE
CLINICAL FOCUS
DURATION
PRIMARY GOAL
Clinical Context
The patient presented with a weight-loss plateau during GLP-1 therapy, alongside NAFLD, neurological disease and previous cancer treatment. Clinical priorities were to preserve lean muscle, restore metabolic flexibility and achieve sustainable weight loss through measurement-informed intervention.
Baseline Assessment
- Zero fat oxidation at rest
- Complete reliance on glucose as fuel source
- Suppressed resting metabolic rate
- Energy intake below measured requirements
- Metabolic adaptation consistent with prolonged energy restriction
Intervention
Interventions were guided by objective metabolic measurement and ongoing reassessment.
- Objective metabolic assessment via ECAL indirect calorimetry
- Personalised nutrition recalibration based on measured RMR
- Targeted fat oxidation strategy
- Ongoing metabolic monitoring and reassessment
Key Metabolic Findings
Fat Oxidation
Weight Change
Muscle Loss
Body Measurements
Repeat metabolic assessment confirmed restoration of fat oxidation and metabolic flexibility while preserving lean tissue throughout treatment.
Outcomes
Interventions were guided by objective metabolic measurement and ongoing reassessment.
- Objective metabolic assessment via ECAL indirect calorimetry
- Personalised nutrition recalibration based on measured RMR
- Targeted fat oxidation strategy
- Ongoing metabolic monitoring and reassessment
Patient Reported Outcome
Interventions were guided by objective metabolic measurement and ongoing reassessment.
- Objective metabolic assessment via ECAL indirect calorimetry
- Personalised nutrition recalibration based on measured RMR
- Targeted fat oxidation strategy
- Ongoing metabolic monitoring and reassessment
Clinical Insight
This case demonstrates that GLP-1 weight-loss plateaus can have identifiable metabolic causes. Objective measurement revealed complete suppression of fat oxidation, a finding invisible without metabolic testing.
Targeted intervention restored fat metabolism and resumed clinical progress, confirming that measurement-guided adjustment can overcome pharmacological plateaus.